MHRA approves Leqselvi for severe alopecia areata
On 10 March 2026, the Medicines and Healthcare products Regulatory Agency, or MHRA, approved Leqselvi, the brand name for deuruxolitinib, for adults with severe alopecia areata. For people living with the condition, that means there is now another prescription treatment option in the UK. If you are meeting these terms for the first time, the key point is straightforward. This is a medicine designed to reduce the inflammation linked to alopecia areata so that hair can grow back in some patients.
Alopecia areata is not the same as everyday hair thinning or routine shedding. The MHRA says it is a disease in which the body's own immune system attacks hair follicles. That attack causes inflammation, and the result can be hair loss on the scalp, the face and other parts of the body. That is worth pausing on, because it changes how you read the story. This is not a cosmetic issue in the usual sense; it is an immune condition, and that is why treatment focuses on calming the body's inflammatory response.
Deuruxolitinib is part of a group of medicines often described as JAK inhibitors. In the MHRA's account, it works by reducing the activity of enzymes called JAK1, JAK2 and TYK2 relative to JAK3 kinases, which are involved in inflammation at the hair follicle. You do not need to remember all of those names to follow the science. In plain English, the medicine is trying to turn down some of the immune signals around the hair follicle. If that inflammation settles, the follicle has a better chance of producing hair again.
Julian Beach, the MHRA's Executive Director of Healthcare Quality and Access, said the approval gives adults with alopecia areata another potential treatment option, while stressing that the medicine will remain under close review for safety and effectiveness. That second point matters just as much as the first. Approval is not a promise that a medicine is risk-free; it means the regulator has judged that the benefits justify the risks for the people it is approved to treat. Leqselvi can only be obtained with a prescription, and the recommended dose is one 8 mg tablet taken twice a day. The approval was granted to Sun Pharma UK Limited through the International Recognition Procedure.
The evidence behind the decision came from two pivotal clinical trials involving 1,209 adult patients. Everyone in those studies had alopecia areata with at least 50% hair loss for more than six months. Over 24 weeks, participants received either Leqselvi 8 mg twice daily, deuruxolitinib 12 mg twice daily or a placebo. If you are building your media literacy, placebo is one of those words worth knowing. It means a lookalike treatment with no active medicine, which gives researchers a fair comparison. In both trials, people taking Leqselvi scored higher on a scale used to measure scalp hair than people taking the placebo.
The results sound encouraging, but they are best read carefully rather than dramatically. After 24 weeks, around 30% of subjects had 80% or more scalp hair, and around 23% had 90% or more scalp hair. So what does that really tell us? It tells us the medicine helped a meaningful share of patients with severe alopecia areata. It also tells us that not everyone responded in the same way. This is another treatment option, not a universal fix.
The most common side effects with deuruxolitinib were headache and acne, and the MHRA said these may affect more than 1 in 10 people. That is the sort of detail readers should not skim past. When regulators mention common side effects, they are helping patients weigh benefit against possible downsides before starting treatment. The medicine is also subject to additional monitoring, which is the MHRA's way of saying it wants new safety information to be picked up quickly. Anyone who suspects a side effect is encouraged to speak to a doctor, pharmacist or nurse and to report it through the Yellow Card scheme. The MHRA said the full prescribing information and patient leaflet would appear on its Products website within seven days of approval.
There is also a wider lesson in this approval notice. A medicine story is rarely just a feel-good headline about a breakthrough. It is a chain of evidence, regulation and follow-up checks. In this case, the MHRA approved a new treatment option for adults with severe alopecia areata on 10 March 2026, based on two sizeable trials and with ongoing safety monitoring built in. For readers, that is the most useful way to hold the story in your head. Leqselvi may help some adults regrow hair, and for people affected by severe alopecia areata that matters. But the approval also comes with the usual medical realities: prescription use, side effects, close review and no guarantee that every patient will respond.